Hanwha wins $720 mln biosimilar license deal with Merck
June 12, 2011 at 20:37 PM EDT
SEOUL, June 13 (Reuters) - South Korea's Hanwha Chemical said on Monday it had won a license deal worth $720 million for its biosimilar product with Merck Sharp & Dohme Research Ltd, a subsidiary of U.S. drug firm Merck & Co .
